Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Gastrointestinal Stromal Tumors 7Mastocytosis, Systemic 5Leukemia, Myeloid, Acute 5Recurrence 4Sarcoma 2Neoplasm Metastasis 2Leukemia, Mast-Cell 2Glioma 2Systemic Mastocytosis With an Associated Hematologic Neoplasm 1Neoplasms 1Neoplasm, Residual 1Melanoma 1Mastocytosis 1Lung Neoplasms 1Glioblastoma 1GIST 1Core Binding Factor Acute Myeloid Leukemia 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1

Interventions

vandetanib 1pazopanib 1olverembatinib 1lenvatinib 1avapritinib 1Surgical Procedures, Operative 1Imatinib Mesylate 1Coal Tar 16-chloro-9-(4-methoxy-3,5-dimethylpyridin-2-ylmethyl)-9H-purin-2-ylamine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
GIST × avapritinib × Clear all
NCT03862885 2020-07-27

Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic GIST

Blueprint Medicines Corporation

Approved for marketing
Sarcoma

GIST

Data powered by HemOnc (CC BY 4.0) Colophon âš¡